We are live on ! Find out more
SILO icon

Silo Pharma

14 hedge funds and large institutions have $1.07M invested in Silo Pharma in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

317% more capital invested

Capital invested by funds: $256K → $1.07M (+$814K)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

8% more funds holding

Funds holding: 1314 (+1)

0.49% more ownership

Funds ownership: 0.6%1.09% (+0.49%)

Holders
14
Holders Change
+1
Holders Change %
+7.69%
% of All Funds
0.18%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
3
Reduced
2
Closed
5
Calls
Puts
Net Calls
Net Calls Change

SILO Hedge Fund Activity: Q3 2025 in Review

14 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Silo Pharma (SILO) for Q3 2025, worth a combined $1.07M — up 317% from $256K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new SILO positions and 5 closed out — a net gain of 1 holder — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $635K. The largest seller was Ursa Fund Management, exiting entirely with an estimated $23.6K sold.

  • 14 institutional investors held Silo Pharma (SILO) as of Q3 2025, up from 13 in Q2 2025.
  • Funds reported $1.07M of Silo Pharma stock for Q3 2025, up 317% quarter-over-quarter.
  • 6 funds opened new Silo Pharma positions in Q3 2025 and 5 closed out, a net change of +1 holder.
  • The largest Silo Pharma buyer in Q3 2025 was Anson Funds Management, an estimated $635K added.
  • The largest Silo Pharma seller in Q3 2025 was Ursa Fund Management, an estimated $23.6K sold.

Based on aggregated 13F filings for Q3 2025.